Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Universal Health Services, Inc. (UHS), Alnylam Pharmaceuticals, Inc. (ALNY), Alere Inc (ALR): Health Care Companies Built for Growth

Page 1 of 2

The health care sector has been one of the best performing sectors of 2013. Investors are excited about the sector, and they are willing to put their money into health care companies. The Health Care Select Sector SPDR (XLV), an ETF, has risen more than 26% since the beginning of 2013.

However, many individual companies in this sector have surpassed the return posted by the ETF. Among these companies, Universal Health Services, Inc. (NYSE:UHS)Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and Alere Inc (NYSE:ALR) are my favorite stocks. These companies represent different industries in the health care sector and have great prospects going forward.

Performance metrics support this hospital

Universal Health Services, Inc. (NYSE:UHS) owns and operates acute care hospitals, behavioral health centers, ambulatory health centers, surgical hospitals, and radiation oncology centers. Its second-quarter results were impressive as it was able to beat expectations on both top and bottom lines. On a year-over-year basis, the company’s revenues and EPS figures expanded.

One of the major ways hospitals make money is through inpatient revenues. This revenue is derived from patients who come and stay at a hospital, while receiving treatment for their health problems. The average revenue per occupied bed metric is used to determine how well a hospital is making inpatient revenues.

Universal Health Services, Inc. (NYSE:UHS) derives approximately 30% of its revenues from behavioral health hospitals. The number of licensed beds in these hospitals is more than three times more than the acute hospitals. The occupancy rate in these hospitals is close to 75% whereas the occupancy rate in acute hospitals is close to 54%. The greatest factor, however, is the average length of stay. Patients stay, on average, 13.5 days in the behavioral hospitals and 4.5 days in the acute hospitals. This drives up the weighted average length of stay at UHS.

Source: Company SEC filings.

The above chart shows UHS’ performance in comparison to two other major players in the hospital industry; Community Health Systems (CYH) and HCA Holdings (HCA). The higher average length of stay and occupancy rates at Universal Health Services, Inc. (NYSE:UHS) lead to strong average revenue per occupied bed.

Innovative solutions set to become profitable

Alere Inc (NYSE:ALR) develops products that allow patients to extend their diagnosis from the lab and doctor’s office to the comfort of their homes. Alere’s programs allow health care providers instant access to diagnostic results, helping them to make timely decisions. The purpose of Alere’s offerings is to reduce hospital visits and health care costs for their patients.

The company leading near-patient diagnostics focus on cardiology, toxicology, and infectious diseases. What interests me is the company’s move into proving diagnostic solutions for diabetics. Alere Inc (NYSE:ALR) has partnered with AT&T and WellDoc in this regard. The 300,000 diabetics served by Alere will now have access to WellDoc’s breakthrough application known as DiabetesManager. The application is the only one that has been cleared by the regulatory authorities for real-time type 2 diabetes medication and coaching. Through the application’s point-of-care diagnostics, health care providers and patients would be able to identify the primary cause of the health care crisis and work toward eliminating it.

The company has taken on debt to finance its acquisitions in the earlier years. Alere Inc (NYSE:ALR) CEO Ron Zwanziger has stated that the company formation is essentially complete, and his next focus will be on deleveraging Alere’s balance sheet. An activist investor has also proposed the sale of the company’s drug testing business, which can bring up to $2.5 billion into the company and help it pay its debt liabilities. Things are looking positive for this company.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!